Systemic Sclerosis Sine Scleroderma: A Time of Reappraisal.

IF 3.6 2区 医学 Q2 RHEUMATOLOGY Journal of Rheumatology Pub Date : 2024-11-01 DOI:10.3899/jrheum.2023-1113
Anastasios Makris, Alexandros Panagiotopoulos, Oliver Distler, Petros P Sfikakis
{"title":"Systemic Sclerosis Sine Scleroderma: A Time of Reappraisal.","authors":"Anastasios Makris, Alexandros Panagiotopoulos, Oliver Distler, Petros P Sfikakis","doi":"10.3899/jrheum.2023-1113","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Systemic sclerosis sine scleroderma (ssSSc), formally described in 1962, is a subset of SSc that, unlike limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) forms, lacks skin fibrosis. According to the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria, SSc can be diagnosed in the absence of skin thickening, even if this is expected to develop later in disease course. Driven by a fatal case of ssSSc with cardiac involvement, we analyzed published data on ssSSc prevalence and severity.</p><p><strong>Methods: </strong>A systematic literature review and qualitative synthesis of SSc cohorts with data on ssSSc were performed.</p><p><strong>Results: </strong>Thirty-five studies involving a total of 25,455 patients with SSc, published between 1976 and 2023, were identified. Although different definitions were used, the mean prevalence of ssSSc was almost 10% (range 0-23%), with the largest study reporting a cross-sectional prevalence of 13%. In 5 studies with a follow-up period of up to 9 years, reclassification of ssSSc into lcSSc or dcSSc ranged 0-28%. Interstitial lung disease, pulmonary arterial hypertension, scleroderma renal crisis, and cardiac diastolic dysfunction were present in 46% (range 9.3-59.1%), 15% (range 5.9-24.6%), 5% (range 1.6-24.6%), and 26.5% (range 1.8-40.7), respectively, of patients with ssSSc. Survival across studies was comparable to lcSSc and better than dcSSc.</p><p><strong>Conclusion: </strong>Published data on ssSSc vary widely on prevalence, clinical expression, and prognosis, partly due to underdiagnosis and misclassification. Although classification criteria should not affect appropriate management of patients, updated ssSSc subclassification criteria that takes into account time from disease onset should be considered.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3899/jrheum.2023-1113","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Systemic sclerosis sine scleroderma (ssSSc), formally described in 1962, is a subset of SSc that, unlike limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) forms, lacks skin fibrosis. According to the 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria, SSc can be diagnosed in the absence of skin thickening, even if this is expected to develop later in disease course. Driven by a fatal case of ssSSc with cardiac involvement, we analyzed published data on ssSSc prevalence and severity.

Methods: A systematic literature review and qualitative synthesis of SSc cohorts with data on ssSSc were performed.

Results: Thirty-five studies involving a total of 25,455 patients with SSc, published between 1976 and 2023, were identified. Although different definitions were used, the mean prevalence of ssSSc was almost 10% (range 0-23%), with the largest study reporting a cross-sectional prevalence of 13%. In 5 studies with a follow-up period of up to 9 years, reclassification of ssSSc into lcSSc or dcSSc ranged 0-28%. Interstitial lung disease, pulmonary arterial hypertension, scleroderma renal crisis, and cardiac diastolic dysfunction were present in 46% (range 9.3-59.1%), 15% (range 5.9-24.6%), 5% (range 1.6-24.6%), and 26.5% (range 1.8-40.7), respectively, of patients with ssSSc. Survival across studies was comparable to lcSSc and better than dcSSc.

Conclusion: Published data on ssSSc vary widely on prevalence, clinical expression, and prognosis, partly due to underdiagnosis and misclassification. Although classification criteria should not affect appropriate management of patients, updated ssSSc subclassification criteria that takes into account time from disease onset should be considered.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
无硬皮病的系统性硬化症:重新评估的时机。
目的:无硬皮病的系统性硬化症(ssSSc)于 1962 年被正式描述,是 SSc 的一个亚型,与局限型(lcSSc)和弥漫型皮肤病(dcSSc)不同,它没有皮肤纤维化。根据 2013 年 ACR/EULAR 标准,在没有皮肤增厚的情况下也可诊断为 SSc,即使皮肤增厚预计会在病程后期出现。在一例心脏受累的致命性 SSSC 病例的推动下,我们分析了有关 SSSC 患病率和严重程度的已发表数据:方法:我们对有 ssSSc 数据的 SSc 队列进行了系统的文献综述和定性分析:结果:共发现了 35 项研究,涉及 25,455 名 SSc 患者,这些研究发表于 1976 年至 2023 年之间。尽管采用了不同的定义,但ssSSc的平均患病率接近10%(范围为0-23%),其中最大的一项研究报告的横断面患病率为13%。在随访期长达 9 年的 5 项研究中,将 ssSSc 重新分类为 lcSSc 或 dcSSc 的比例从 0% 到 28% 不等。46%(范围 9.3-59.1%)、15%(范围 5.9-24.6%)、5%(范围 1.6-24.6%)和 26.5%(范围 1.8-40.7%)的 ssSSc 患者存在间质性肺病、肺动脉高压、硬皮病肾危象和心脏舒张功能障碍。各项研究的生存率与lcSSc相当,优于dcSSc:已发表的关于 ssSSc 的数据在患病率、临床表现和预后方面差异很大,部分原因是诊断不足和分类错误。虽然分类标准不应影响对患者的适当管理,但应考虑更新 ssSSc 亚分类标准,将发病时间考虑在内。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Rheumatology
Journal of Rheumatology 医学-风湿病学
CiteScore
6.50
自引率
5.10%
发文量
285
审稿时长
1 months
期刊介绍: The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman. The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 41 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.
期刊最新文献
Disparities in time to diagnosis of Radiographic Axial Spondyloarthritis. Potential Efficacy of Janus Kinase Inhibitors in the Treatment of a Patient With Coexisting Peripheral and Axial Spondyloarthritis and Ulcerative Colitis. Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study. Scleroderma Renal Crisis: Clues From the Physical Exam. Systemic Sclerosis Sine Scleroderma: A Time of Reappraisal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1